N-[2-(4,6-dichloro-5-pyrimidinyl)ethyl]-2-methyl-3-pyridinamine | 1001398-59-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-[2-(4,6-dichloro-5-pyrimidinyl)ethyl]-2-methyl-3-pyridinamine
• 英文别名: N-[2-(4,6-dichloropyrimidin-5-yl)ethyl]-2-methylpyridin-3-amine
• CAS: 1001398-59-9
• 化学式: C₁₂H₁₂Cl₂N₄
• 分子量: 283.16
• InChiKey: HBUXNWLDIVXTAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[2-(4,6-dichloro-5-pyrimidinyl)ethyl]-2-methyl-3-pyridinamine 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium tert-butylate 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 20.0h， 生成 1-methylethyl 4-{[7-(2-methyl-3-pyridinyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}-1-piperidinecarboxylate
  参考文献：
  名称：

  Discovery of 6,7-Dihydro-5H-pyrrolo[2,3-a]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists

  摘要：

  GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119 (GPR119) agonists, and lead optimization efforts led to the identification of 1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate (GSK1104252A) (3), a potent and selective GPR119 agonist. Compound 3 showed excellent pharmacokinetic properties and sufficient selectivity with in vivo studies supporting a role for GPR119 in glucose homeostasis in the rodent. Thus, 3 appeared to modulate the enteroinsular axis, improve glycemic control, and strengthen previous suggestions that GPR119 agonists may have utility in the treatment of type 2 diabetes.

  DOI：

  10.1021/jm301404a
• 作为产物：
  描述：

  5-烯丙基-4,6-二氯嘧啶 在 potassium osmate(VI) dihydrate 、 sodium periodate 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 23.0h， 生成 N-[2-(4,6-dichloro-5-pyrimidinyl)ethyl]-2-methyl-3-pyridinamine
  参考文献：
  名称：

  Discovery of 6,7-Dihydro-5H-pyrrolo[2,3-a]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists

  摘要：

  GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119 (GPR119) agonists, and lead optimization efforts led to the identification of 1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate (GSK1104252A) (3), a potent and selective GPR119 agonist. Compound 3 showed excellent pharmacokinetic properties and sufficient selectivity with in vivo studies supporting a role for GPR119 in glucose homeostasis in the rodent. Thus, 3 appeared to modulate the enteroinsular axis, improve glycemic control, and strengthen previous suggestions that GPR119 agonists may have utility in the treatment of type 2 diabetes.

  DOI：

  10.1021/jm301404a

文献信息

• WO2008/8895
  申请人：——

  公开号：——

  公开（公告）日：——
• CHEMICAL COMPOUNDS
  申请人：KATAMREDDY Subba R.

  公开号：US20090318477A1

  公开（公告）日：2009-12-24

  The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
• US8222261B2
  申请人：——

  公开号：US8222261B2

  公开（公告）日：2012-07-17
• Discovery of 6,7-Dihydro-5<i>H</i>-pyrrolo[2,3-<i>a</i>]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists
  作者：Subba R. Katamreddy、Andrew J. Carpenter、Carina E. Ammala、Eric E. Boros、Ron L. Brashear、Celia P. Briscoe、Sarah R. Bullard、Richard D. Caldwell、Christopher R. Conlee、Dallas K. Croom、Shane M. Hart、Dennis O. Heyer、Paul R. Johnson、Jennifer A. Kashatus、Doug J. Minick、Gregory E. Peckham、Sean A. Ross、Shane G. Roller、Vicente A. Samano、Howard R. Sauls、Sarva M. Tadepalli、James B. Thompson、Yun Xu、James M. Way

  DOI：10.1021/jm301404a

  日期：2012.12.27

  GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119 (GPR119) agonists, and lead optimization efforts led to the identification of 1-methylethyl 4-(7-[2-fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate (GSK1104252A) (3), a potent and selective GPR119 agonist. Compound 3 showed excellent pharmacokinetic properties and sufficient selectivity with in vivo studies supporting a role for GPR119 in glucose homeostasis in the rodent. Thus, 3 appeared to modulate the enteroinsular axis, improve glycemic control, and strengthen previous suggestions that GPR119 agonists may have utility in the treatment of type 2 diabetes.